معرفی
Marc J. van de Vijver is a Full Professor at both the University of Amsterdam (UvA) and Vrije Universiteit Amsterdam (VU) through Amsterdam University Medical Centers (Amsterdam UMC), with dual appointments in the Cancer Center Amsterdam (CCA) across Cancer Biology and Immunology and Imaging and Biomarkers programs, plus Pathology departments at both universities. His distinguished career spans decades of groundbreaking research in breast cancer genomics and molecular pathology.
Dr. van de Vijver's research primarily focuses on breast cancer genomics, gene expression profiling, and molecular pathology. His seminal work established the 70-gene signature (MammaPrint) for predicting breast cancer outcomes, revolutionizing personalized treatment approaches. His research spans internal medicine, oncology, and computational biology, with recent expansion into pancreatic ductal adenocarcinoma and pan-cancer genomic analyses. He has made significant contributions to understanding cancer heterogeneity, biomarker discovery, and the molecular mechanisms driving cancer progression and treatment resistance.
Analysis of his publication trends reveals a consistent focus on breast cancer genomics throughout his career, with increasing integration of computational approaches and expansion into broader cancer genomics. His early work established foundational gene expression signatures, while recent research explores epigenetic alterations, non-coding RNA, and cross-cancer genomic analyses. The high citation counts of his work (over 86,000 total) reflect its significant impact on both basic cancer research and clinical practice.
Dr. van de Vijver's scientific achievements are reflected in his D-Index of 96 and ranking among the world's top cancer researchers. His work has directly influenced clinical guidelines, particularly in breast cancer diagnostics and HER2 testing.
As a mentor and collaborator, Dr. van de Vijver has worked with numerous leading researchers globally, contributing to major multi-institutional studies and cancer genome projects. His dual appointments at Amsterdam UMC reflect the integrated nature of cancer research in Amsterdam, where basic science and clinical applications are closely connected.
While specific lab details aren't provided in the available information, Dr. van de Vijver leads a research program deeply embedded in Amsterdam UMC's pathology and cancer research infrastructure, with strong connections to both basic science and clinical departments.
